Literature DB >> 30544185

Intra-Cavitary Contrast-Enhanced Ultrasound: A Novel Radiation-Free Method for Detecting Abscess-Associated Penetrating Disease in Crohn's Disease.

Ren Mao1,2, Yu-Jun Chen3, Bai-Li Chen1, Xiao-Hua Xie3, Yao He1, Shu-Ling Chen3, Ming Xu3, Xue-Hua Li4, Jian Zhang5, Xin-Ming Song6, Zhi-Rong Zeng1, Jordi Rimola7, Florian Rieder2, Shomron Ben-Horin1,8, Min-Hu Chen1, Xiao-Yan Xie3.   

Abstract

BACKGROUND AND AIM: Penetrating disease is a common condition complicating Crohn's disease [CD]. Establishing the presence of a fistula and the anatomical definition of the fistulous tracts are essential for deciding on appropriate treatment strategies. We aimed to assess the diagnostic accuracy of intra-cavitary contrast-enhanced ultrasound [IC-CEUS] for the detection of a fistulous tract associated with abscesses in CD patients.
METHODS: In this prospective cohort study, consecutive CD patients suspected of having an intra-abdominal abscess, who were referred for US-guided aspiration were recruited. IC-CEUS was performed by injecting diluted contrast agent [SonoVue] into the abscess cavity immediately following the ultrasound-guided needle abscess aspiration and drainage. The diagnostic accuracy of IC-CEUS in demonstrating the presence of fistulous tracts was compared with that of computed tomography enterography/magnetic resonance enterography [CTE/MRE], using surgical and gross pathological findings as the reference standard.
RESULTS: Thirty-one patients who underwent IC-CEUS and subsequent surgery were included in the final analysis. IC-CEUS demonstrated fistulous/sinus tracts in 26 of 31 participants with a sensitivity and specificity of 86.7 % (95% confidence interval [CI], 68.4-95.6%) and 100% [95% CI, 5.5-100.0%], respectively. Moreover, IC-CEUS correctly demonstrated fistulous/sinus tracts in 13 participants without delineation of fistulous/sinus tracts on CTE/MRE. Combining IC-CEUS and CTE/MRE, the fistula/sinus tract was clearly demonstrated in 29 patients [93.5%, 29/31]. The mean duration of the IC-CEUS procedure was 8.6 min [range 5.0-12.0]. No severe adverse events occurred during the IC-CEUS procedure.
CONCLUSION: In this pilot study, IC-CEUS accurately delineated the anatomical definition of fistulous/sinus tracts associated with intra-abdominal abscesses in CD patients. As a radiation-free and safe technique, IC-CEUS may be used as an alternative/adjunctive method to CTE/MRE for detecting penetrating disease in patients with CD.
Copyright © 2018 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Contrast-enhanced ultrasound; Crohn’s disease; Fistulas

Mesh:

Substances:

Year:  2019        PMID: 30544185     DOI: 10.1093/ecco-jcc/jjy209

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  3 in total

Review 1.  Intracavitary contrast-enhanced ultrasonography in children: review with procedural recommendations and clinical applications from the European Society of Paediatric Radiology abdominal imaging task force.

Authors:  Damjana Ključevšek; Michael Riccabona; Lil-Sofie Ording Müller; Magdalena Maria Woźniak; Stéphanie Franchi-Abella; Kassa Darge; Hans-Joachim Mentzel; Aikaterini Ntoulia; Fred Efraim Avni; Marcello Napolitano; Luisa Lobo; Annemieke Simone Littooij; Thomas Angell Augdal; Costanza Bruno; Beatrice Maria Damasio; Donald Ibe; Samuel Stafrace; Philippe Petit
Journal:  Pediatr Radiol       Date:  2020-02-13

2.  Cholecystoduodenal fistula identified on oral contrast-enhanced ultrasound.

Authors:  Adam Young; Gibran Timothy Yusuf; Cheng Fang; Anna Metafa; Shweta Gupta; Paul Singh Sidhu
Journal:  J Ultrasound       Date:  2020-11-07

Review 3.  Contrast-enhanced ultrasound of the pediatric bowel.

Authors:  Ami Gokli; Jonathan R Dillman; Paul D Humphries; Damjana Ključevšek; Hans-Joachim Mentzel; Erika Rubesova; Marcelo S Takahashi; Sudha A Anupindi
Journal:  Pediatr Radiol       Date:  2021-05-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.